Please use this identifier to cite or link to this item: http://hdl.handle.net/10311/1826
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTshikuka, Jose Gaby-
dc.contributor.authorRankgoane-Pono, Goabaone-
dc.contributor.authorMagafu, Mgaywa Gilbert Mjungu Damas-
dc.contributor.authorMasupe, Tiny-
dc.contributor.authorMolefi, Mooketsi-
dc.contributor.authorNsikungu-Kalukul, Maurice-
dc.contributor.authorTlhakanelo, John Thato-
dc.contributor.authorHamda, Shimeles Genna-
dc.contributor.authorSetlhare, Vincent-
dc.date.accessioned2018-11-15T07:55:13Z-
dc.date.available2018-11-15T07:55:13Z-
dc.date.issued2018-04-10-
dc.identifier.citationTshikuka, J.G. et al. (2018) Relationship between combination antiretroviral therapy regimens and diabetes mellitus-related comorbidities among HIV patients in Gaborone Botswana. BMC Public Health, Vol. 18, No. 464, pp. 1-9en_US
dc.identifier.issn1471-2458-
dc.identifier.urihttp://hdl.handle.net/10311/1826-
dc.description.abstractBackground: Combination antiretroviral therapy (cARTs) regiments are known to prolong the recipients’ life even though they are risk factors for diabetes mellitus-related comorbidities (DRCs). We sought to: (i) examine cART relationship with DRCs among patients attending HIV clinics in Gaborone, Botswana (which cART regimens are associated with shorter/longer time to the event), (ii) characterize patients’ underlying biomedical and demographic risk factors of DRC and identify the most important, (iii) investigate survival of patients on different cART regimens in the presence of these risk factors. Methods: Data from two major HIV clinics in Botswana were reviewed. Relationships between different cART regimens and DRCs were investigated among 531 recipients. Recipients’ DRC risk factors were identified. Cox regression model was run. Unadjusted and adjusted hazard ratios were computed, and hazard and survival functions for different cART regimens were plotted. Results: Major findings were: patients on second- and third-line cART were less likely to develop DRCs earlier than those on first-line cART. Patients with CD4 count ≤ 200 cells/mm3 at cART initiation were more likely to develop DRCs earlier than those who had CD4 count > 200 cells/mm3. Overweight patients at cART initiation had a higher risk of developing DRCs earlier than those who had normal body mass index. Males had a lower risk of developing DRCs earlier than females. Conclusion: The risk of new onset of DRC among cART recipients is a function of the type of cART regimen, duration of exposure and patients’ underlying biomedical and demographic DRC risk factors. The study has provided a survival model highlighting DRCs’ significant prognostic factors to guide clinical care, policy and management of recipients of cARTs. Further studies in the same direction will likely improve the survival to the development of DRC of every cART recipient in this community.en_US
dc.language.isoenen_US
dc.publisherBioMed Central, www.biomedcentral.comen_US
dc.subjectDiabetes mellitus-related comorbiditiesen_US
dc.subjectHIV patientsen_US
dc.subjectrecipients underlying risk factorsen_US
dc.subjectsurvival functionen_US
dc.subjectcombination antiretroviral therapyen_US
dc.titleRelationship between combination antiretroviral therapy regimens and diabetes mellitus-related comorbidities among HIV patients in Gaborone Botswanaen_US
dc.typePublished Articleen_US
dc.linkhttps://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-018-5232-0en_US
Appears in Collections:Research articles (School of Medicine)

Files in This Item:
File Description SizeFormat 
Tshikuka _BMCPH_2018.pdf514.59 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.